Although LDL cholesterol reduction serves as a cornerstone of prevention of coronary disease ([@B1]), the coronary heart disease (CHD) risk may be better predicted by measures of atherogenic particles, such as non--HDL cholesterol ([@B2]), apolipoprotein B (apoB) ([@B3]), or LDL particle concentration ([@B4][@B5]--[@B6]).

Patients with the metabolic syndrome may have relatively normal LDL cholesterol when LDL particle concentration is elevated because these patients have a preponderance of small, cholesterol-poor LDL particles ([@B7]). Thus, LDL cholesterol may underestimate risk in patients with the metabolic syndrome ([@B2],[@B8]). Likewise, in men with CHD, low HDL cholesterol (≤1.04 mmol/l \[40 mg/dl\]), and often many other characteristics of the metabolic syndrome, new CHD events were correlated with high LDL particle concentration but not LDL cholesterol, and a low HDL particle concentration was more strongly inversely correlated with CHD events than was HDL cholesterol ([@B5]).

This exploratory analysis of the Comparative Study with Rosuvastatin in Subjects with Metabolic Syndrome (COMETS, 4522IL/0069) ([@B9]) compares the effects of rosuvastatin (RSV) and atorvastatin (ATV) on lipoprotein particle concentrations and cholesterol levels in patients with the metabolic syndrome. We sought to determine the efficacy of statin therapy in achieving LDL cholesterol targets set by the National Cholesterol Education Program Adult Treatment Panel III (ATP III) and the corresponding numbers of patients who achieved LDL particle concentration targets below the 50th percentile (\<1,300 nmol/l) and below the 20th percentile (\<1,000 nmol/l) based on values established by the Multi-Ethnic Study of Atherosclerosis (MESA) ([@B10]).

RESEARCH DESIGN AND METHODS
===========================

The study population included men and women, aged ≥18 years, with the metabolic syndrome as defined by ATP III criteria ([@B1]) ([Table 1](#T1){ref-type="table"}). Other inclusion criteria included LDL cholesterol 3.36--6.48 mmol/l (130--250 mg/dl) and a 10-year CHD risk score \>10%. Exclusion criteria included triglycerides ≥5.65 mmol/l (500 mg/dl), use of lipid-lowering therapy within 6 months, CHD or other atherosclerotic disease, diabetes, and liver dysfunction.

###### 

Demographic and clinical characteristics of the study population

                                                            10/20 mg RSV   10/20 mg ATV   Placebo/20 mg RSV
  --------------------------------------------------------- -------------- -------------- -------------------
  *n*                                                       136            119            63
  Age (years)                                               58.6 ± 9.3     58.2 ± 9.7     58.5 ± 9.0
  Male sex                                                  87 (64.0)      78 (65.5)      43 (68.3)
  Caucasian race                                            134 (98.5)     116 (97.5)     60 (95.2)
  BMI (kg/m^2^)                                             30.5 ± 3.8     31.0 ± 3.5     30.4 ± 4.0
  Metabolic syndrome criteria                                                             
      Abdominal obesity[\*](#TF1-1){ref-type="table-fn"}    123 (90.4)     116 (97.5)     57 (90.5)
      Triglycerides ≥1.70 mmol/l (150 mg/dl)                110 (80.9)     81 (68.1)      52 (82.5)
      Low HDL cholesterol[†](#TF1-2){ref-type="table-fn"}   73 (53.7)      54 (45.4)      24 (38.1)
      Blood pressure ≥130/85 mmHg                           128 (94.1)     113 (95.0)     60 (95.2)
      Fasting glucose 6.11--6.94 mmol/l                     33 (24.3)      29 (24.4)      14 (22.2)

Data are means ± SD or*n*(%).

\*Waist circumference \>102 cm for men and \>88 cm for women.

†HDL cholesterol \<1.04 mmol/l (40 mg/dl) for men and \<1.30 mmol/l (50 mg/dl) for women.

The study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice. Study procedures were approved by ethics committees, and all patients provided informed, written consent.

Patients were randomly assigned at 56 clinical centers in Europe and the U.S. into a double-blind, double-dummy,parallel-group study ([@B9]). After a 4-week dietary lead-in period, patients were randomly assigned (2:2:1) to 10 mg/day RSV (RSV10), 10 mg/day ATV (ATV10), or placebo for 6 weeks. After the 6-week treatment period, patients treated with RSV10 or placebo received 20 mg/day RSV (RSV20), and patients previously treated with ATV10 received 20 mg/day ATV (ATV20) for another 6 weeks.

Fasting blood samples were collected at baseline and at 6 and 12 weeks. Lipoprotein particle concentrations were measured by automated nuclear magnetic resonance spectroscopy (LipoScience, Raleigh, NC) ([@B10]). Lipids and lipoproteins were measured at a central laboratory certified for lipid analysis by the Standardization Program of the Centers for Disease Control and Prevention and the National Heart, Lung, and BloodInstitute (Medical Research Laboratories International, Zaventum, Belgium, and Highland Heights, KY). β-Quantification was performed to provide the most accurate measure of LDL cholesterol in the presence of high triglyceride levels. Plasma samples were overlaid with normal saline and ultracentrifuged (105,000*g*) for 18 to 22 h at 10°C; centrifuge tubes were sliced to separate the top (density \<1.006; VLDL) and bottom (density \>1.006; LDL and HDL cholesterol) fractions. The cholesterol contents of the bottom fraction and whole plasma were measured using an automated analyzer (Hitachi 747). For determination of HDL cholesterol, plasma was treated with Mn^2+^ and heparin to precipitate chylomicrons, VLDL, and LDL cholesterol. After centrifugation, the HDL cholesterol content of the supernatant was measured in an automated analyzer. VLDL cholesterol was calculated as total cholesterol from whole plasma minus (LDL + HDL cholesterol) from the bottom ultracentrifugation fraction. LDL cholesterol was calculated as (LDL + HDL cholesterol) from the bottom ultracentrifugation fraction minus HDL cholesterol from the precipitation assay. Non-HDL cholesterol was calculated as total cholesterol from whole plasma minus HDL cholesterol from the precipitation assay. Triglycerides weremeasured using the automatic analyzer, and apolipoproteins were measured by immunonephelometry.

Statistical analysis
--------------------

Data from the per-protocol patient population were used for this exploratory analysis because a complete laboratory dataset was required for each patient. Statistical significance of least-squares differences among treatment groups was determined with an ANCOVA model that included controls for treatment, study center, and baseline value. The statistical significance of differences in goal attainment was determined by the χ^2^test.

RESULTS
=======

The first patient was enrolled into the study on 16 May 2002, and the last patient completed the study on 30 September 2003. The population included 318 patients at baseline, of whom 136 were randomly assigned to RSV10, 119 to ATV10, and 63 to placebo. At week 6, the per-protocol population included 278 patients (RSV10, *n* = 122; ATV10, *n* = 101; and placebo, *n* = 55); at the end of the study (12 weeks); data for 257 patients were available for analysis (RSV20, *n* = 166, and ATV20, *n* = 91). Baseline lipid and lipoprotein parameters were well balanced among patients in the three treatment arms ([Table 2](#T2){ref-type="table"}).

###### 

Baseline lipoprotein levels

  Parameter                    Rosuvastatin   Atorvastatin   Placebo
  ---------------------------- -------------- -------------- -------------
  *n*                          122            101            55
  HDL-C (mmol/l)               1.1 ± 0.2      1.2 ± 0.2      1.2 ± 0.2
  HDL-P (μmol/l)               28 ± 6         29 ± 6         31 ± 6
  ApoA-I (mg/dl)               146 ± 26       151 ± 25       152 ± 21
  LDL-C (mmol/l)               4.3 ± 0.6      4.4 ± 0.6      4.4 ± 0.7
  Non-HDL-C (mmol/l)           5.3 ± 0.7      5.3 ± 0.8      5.4 ± 0.8
  Total cholesterol (mmol/l)   6.4 ± 0.7      6.5 ± 0.8      6.6 ± 0.8
  LDL-P (nmol/l)               1,962 ± 383    1,869 ± 367    2,018 ± 440
  ApoB (mg/dl)                 160 ± 24       161 ± 26       164 ± 28
  VLDL-P (nmol/l)              109 ± 35       104 ± 37       105 ± 34
  Triglycerides (mmol/l)       2.3 ± 0.8      2.1 ± 0.7      2.5 ± 0.9
  C-reactive protein (mg/l)    2.2            2.9            2.6

Data are means ± SD or median. HDL-C, HDL cholesterol; HDL-P, HDL particle concentration; LDL-C, LDL cholesterol; LDL-P, LDL particle concentration; non-HDL-C, non-HDL cholesterol; VLDL-P, VLDL particle concentration.

Effects on LDL and VLDL
-----------------------

Compared with placebo, both RSV10 and ATV10 significantly (*P* \< 0.001) reduced LDL cholesterol, LDL particle concentration, apoB, and non-HDL cholesterol ([Fig. 1](#F1){ref-type="fig"}) after 6 weeks of treatment. RSV was more effective than ATV in reducing LDL cholesterol (*P* \< 0.001), LDL particle concentration (*P* \< 0.05), and non-HDL cholesterol (*P* \< 0.01) after 6 and 12 weeks. With either statin, percent reductions in LDL particle concentration were smaller than reductions in LDL cholesterol. This difference was apparent at 6 weeks (34 vs. 45% for RSV10 and 30 vs. 38% for ATV10) and became more pronounced after 12 weeks (38 vs. 50% for RSV20 and 33 vs. 44% for ATV20). Reductions in LDL cholesterol, LDL particle concentration, non-HDL cholesterol, and apoB did not differ substantially among patients with higher or lower baseline serum triglycerides ([Table 3](#T3){ref-type="table"}).

![Least-squares mean percentage change from baseline in lipids and lipoproteins by treatment group. ![](cjs2099.jpg), apoA-I; ▩, apoB; ■, HDL cholesterol; ▧, HDL particle concentration; □, LDL cholesterol; ▨, LDL particle concentration; ▤, non--HDL cholesterol; ![](cjs2118.jpg), triglycerides; ![](cjs2088.jpg), VLDL particle concentration.](zdc0060975730001){#F1}

###### 

Baseline lipoprotein levels and percent change from baseline by triglyceride subgroup

  Parameter                                                Baseline triglyceride \<2.26 mmol/l                                   Baseline triglyceride ≥2.26 mmol/l                                                                                                                                                                                                                  
  -------------------------------------------------------- --------------------------------------------------------------------- ------------------------------------- ------- ------------------------------------- ----- --------------------------------------------------------------------- ------------------------------------- ------- ------------------------------------- -----
  *n*                                                      66                                                                    64                                    22      80                                    58    56                                                                    37                                    33      86                                    33
  HDL-C (mmol/l)                                           1.1                                                                   1.2                                   1.3                                                 1.1                                                                   1.1                                   1.1                                           
      % change                                             7[\*](#TF3-1){ref-type="table-fn"}                                    3                                     −1      9[§](#TF3-4){ref-type="table-fn"}     3     12[†](#TF3-2){ref-type="table-fn"}[§](#TF3-4){ref-type="table-fn"}    4                                     4       14                                    11
  HDL-P (μmol/l)                                           28                                                                    29                                    32                                                  29                                                                    29                                    30                                            
      % change                                             12[\*](#TF3-1){ref-type="table-fn"}                                   8                                     2       15[§](#TF3-4){ref-type="table-fn"}    5     14                                                                    13                                    6       21                                    19
  ApoA-I (mg/dl)                                           149                                                                   148                                   152                                                 158                                                                   156                                   154                                           
      % change                                             4                                                                     0.02                                  3       6[‖](#TF3-5){ref-type="table-fn"}     1     5[§](#TF3-4){ref-type="table-fn"}                                     −2                                    1       6                                     4
  LDL-C (mmol/l)                                           165                                                                   168                                   162                                                 171                                                                   176                                   173                                           
      % change                                             −47[‡](#TF3-3){ref-type="table-fn"}[§](#TF3-4){ref-type="table-fn"}   −39[‡](#TF3-3){ref-type="table-fn"}   −3      −52[‖](#TF3-5){ref-type="table-fn"}   −46   −43[‡](#TF3-3){ref-type="table-fn"}[‖](#TF3-5){ref-type="table-fn"}   −37[‡](#TF3-3){ref-type="table-fn"}   2       −49[§](#TF3-4){ref-type="table-fn"}   −42
  Non-HDL-C (mmol/l)                                       5.0                                                                   5.0                                   4.8                                                 5.6                                                                   5.8                                   5.7                                           
      % change                                             −44[‡](#TF3-3){ref-type="table-fn"}[‖](#TF3-5){ref-type="table-fn"}   −37[‡](#TF3-3){ref-type="table-fn"}   −2      −49[‖](#TF3-5){ref-type="table-fn"}   −43   −43[‡](#TF3-3){ref-type="table-fn"}[‖](#TF3-5){ref-type="table-fn"}   −37[‡](#TF3-3){ref-type="table-fn"}   1       −48[‖](#TF3-5){ref-type="table-fn"}   −42
  LDL-P (nmol/l)                                           1,812                                                                 1,736                                 1,691                                               2,140                                                                 2,100                                 2,236                                         
      % change                                             −33[‡](#TF3-3){ref-type="table-fn"}                                   −29[‡](#TF3-3){ref-type="table-fn"}   −1      −37                                   −32   −37[‡](#TF3-3){ref-type="table-fn"}[‖](#TF3-5){ref-type="table-fn"}   −30[‡](#TF3-3){ref-type="table-fn"}   −2      −40                                   −35
  ApoB (mg/dl)                                             152                                                                   153                                   146                                                 169                                                                   175                                   176                                           
      % change                                             −38[‡](#TF3-3){ref-type="table-fn"}                                   −33[‡](#TF3-3){ref-type="table-fn"}   1       −43[‖](#TF3-5){ref-type="table-fn"}   −37   −37[‡](#TF3-3){ref-type="table-fn"}                                   −35[‡](#TF3-3){ref-type="table-fn"}   −1      −42                                   −37
  VLDL-P (nmol/l)                                          95                                                                    89                                    86                                                  126                                                                   130                                   117                                           
      % change                                             −39[‡](#TF3-3){ref-type="table-fn"}                                   −40[‡](#TF3-3){ref-type="table-fn"}   −5      −42                                   −44   −29[‡](#TF3-3){ref-type="table-fn"}                                   −33[‡](#TF3-3){ref-type="table-fn"}   −4      −40                                   −40
  Triglycerides (mmol/l)[¶](#TF3-6){ref-type="table-fn"}   1.8                                                                   1.7                                   1.7                                                 3.0                                                                   2.9                                   3.0                                           
      % change                                             −15[\*](#TF3-1){ref-type="table-fn"}                                  −22[†](#TF3-2){ref-type="table-fn"}   1       −18                                   −24   −30[‡](#TF3-3){ref-type="table-fn"}                                   −26[†](#TF3-2){ref-type="table-fn"}   −7      −30                                   −31

\**P*\< 0.05 vs. placebo.

†*P*\< 0.01 vs. placebo.

‡*P*\< 0.001 vs. placebo.

§*P*\< 0.01 vs. ATV.

‖*P*\< 0.05 vs. ATV.

¶A triglyceride concentration of 2.26 mmol/l corresponds to 200 mg/dl. HDL-C, HDL cholesterol; HDL-P, HDL particle concentration; LDL-C, LDL cholesterol; LDL-P, LDL particle concentration; non-HDL-C, non-HDL cholesterol; VLDL-P, VLDL particle concentration.

Compared with placebo, RSV10 and ATV10 significantly (*P* \< 0.001) reduced VLDL particle concentration and serum triglycerides by 6 weeks ([Fig. 1](#F1){ref-type="fig"}). The two statins were similarly effective in reducing VLDL particle concentration and serum triglycerides at weeks 6 and 12.

Effects on HDL
--------------

Compared with placebo, RSV10 increased HDL particle concentration (15%) and HDL cholesterol (10%) significantly (*P* \< 0.001) ([Fig. 1](#F1){ref-type="fig"}). Although ATV10 also significantly increased HDL particle concentration (6%, *P* = 0.013 vs. placebo), it was not more effective than placebo in increasing HDL cholesterol (4%, *P* = 0.45). RSV was significantly more effective than ATV in increasing HDL particle concentration and HDL cholesterol after 6 and 12 weeks (*P*≤ 0.002). Neither statin showed a statistically significant effect on apoA-I compared with placebo; however, increases in apoA-I were significantly greater with RSV than with ATV at 6 (*P* = 0.001) and 12 weeks (*P* = 0.02) ([Fig. 1](#F1){ref-type="fig"}). In patients with high baseline triglyceride levels, HDL cholesterol, HDL particle concentration, and apoA-I increases with ATV20 appeared higher (4--19%) than in those with low baseline triglycerides (1--5%) ([Table 3](#T3){ref-type="table"}). HDL cholesterol, HDL particle concentration, and apoA-I increases with RSV20 were numerically greater than those with ATV20 regardless of baseline triglyceride levels.

Goal attainment
---------------

Most patients achieved LDL cholesterol \<2.59 mmol/l (\<100 mg/dl), but a significantly higher proportion of patients assigned to RSV achieved this goal (*P* \< 0.01 at 6 weeks and *P* \< 0.0001 at 12 weeks vs. ATV) ([Table 4](#T4){ref-type="table"}). Patients assigned to RSV were also more likely to reach LDL particle concentration \<1,300 nmol/l at 12 weeks (*P* = 0.02 vs. ATV) and LDL particle concentration \<1,000 nmol/l at 6 weeks (*P* = 0.02 vs. ATV). The percentage of patients who attained LDL particle concentration \<1,300 nmol/l was similar to that achieving LDL cholesterol \<2.59 mmol/l (\<100 mg/dl), but fewer patients reached LDL particle concentration \<1,000 nmol/l.

###### 

Number and percentage of patients achieving LDL particle and LDL cholesterol goals

                                  Baseline    6 weeks       12 weeks
  ------------------------------- ----------- ------------- --------------
  LDL-P \<1,000 nmol/l                                      
      Rosuvastatin                0           30/122 (25)   45/166 (27)
      Atorvastatin                0           12/101 (12)   17/91 (19)
      Placebo                     0           1/55 (2)      ---
  LDL-P \<1,300 nmol/l                                      
      Rosuvastatin                4/122 (3)   70/122 (57)   115/166 (69)
      Atorvastatin                3/101 (3)   60/101 (59)   50/91 (55)
      Placebo                     3/55 (5)    1/55 (2)      ---
  LDL cholesterol \<2.59 mmol/l                             
      Rosuvastatin                0           99/162 (61)   185/232 (80)
      Atorvastatin                0           70/151 (46)   85/145 (59)
      Placebo                     0           1/78 (1)      ---

Data are*n*(%). LDL particle concentration (LDL-P) \<1,000 nmol/l corresponds to the 20th percentile and \<1,300 nmol/l to the 50th percentile of values from the MESA study ([@B10]).

CONCLUSIONS
===========

In patients with the metabolic syndrome, statins reduced atherogenic lipoproteins, and reductions generally were higher with RSV than with ATV. RSV increased HDL cholesterol, and both statins increased HDL particle concentration compared with placebo. Increases in HDL cholesterol, HDL particle concentration, and apoA-I were greater with RSV than with ATV (*P* \< 0.001 for all vs. ATV10; *P* \< 0.01 for HDL cholesterol and HDL particle concentration, and *P* \< 0.05 for apoA-I vs. ATV20). A higher proportion of patients assigned to RSV achieved LDL cholesterol \<2.59 mmol/l (\<100 mg/dl); however, even with RSV20, only 27% of these patients with the metabolic syndrome reached comparably low LDL particle concentration levels of \<1,000 nmol/l.

In this population, the magnitude of LDL particle concentration reduction with statins was smaller than that of LDL cholesterol reduction, suggesting that LDL cholesterol may underestimate residual CHD risk in patients with the metabolic syndrome. In contrast, in a dyslipidemic population not selected to have the metabolic syndrome, modest statin-induced reductions in LDL cholesterol (28%) and LDL particle concentration (24%) by pravastatin were more concordant ([@B11]). These observations support the possibility that LDL particle goals, assessed by nuclear magnetic resonance or apoB measurement, may offer an advantage over LDL cholesterol goals ([@B2],[@B12]), particularly in patients with the metabolic syndrome.

Although the statin effect on LDL particle concentration was attenuated in comparison with the effect on LDL cholesterol, the fractional HDL particle concentration response was higher than that of HDL cholesterol. ApoA-I levels were only modestly increased (4--6% by RSV and −1 to 2% by ATV), consistent with the known heterogeneity of HDL particles with regard to apoA-I and lipid content ([@B13]). Thus, the observed treatment effects could reflect an increase in relatively cholesterol-depleted HDL particles. Whether this cholesterol depletion is due to higher cholesterol ester transfer protein--mediated reverse cholesterol transport activity or to reduced cholesterol uptake from the periphery is uncertain. A recent report described the apparent dysfunction of HDL in patients with the metabolic syndrome ([@B14]); thus, any mechanistichypothesis would not necessarily apply to other patient groups. Restoring HDL function may be particularly valuable in these patients, but the utility of statins for this purpose remains to be established.

Strengths of this analysis include the randomized, blinded, and placebo-controlled design and the increasing clinical relevance of the patient population studied. Several possible limitations should be noted. First, the 12-week assessments did not include a placebo comparator. However, the objective nature of the measurements and the small magnitude of changes observed with placebo in the first 6-week period suggest that changes by 12 weeks can be attributed to statin therapy. Second, patients in the RSV20 group included both those treated previously with RSV10 and those given placebo previously, possibly leading to heterogeneity in clinical response. Third, the study population was almost entirely Caucasian (392 of 401; 98%); thus, the findings may not apply to other racial and ethnic groups. Finally, in view of the exploratory nature of this post hoc analysis, results should be interpreted cautiously.

The paradigm that the concentration of atherogenic particles is a more important determinant of cardiovascular risk than conventional lipid measures such as LDL cholesterol ([@B3],[@B15]) implies that measurements such as LDL particle concentration or apoB may move toward the center of future risk assessment. In nearly all prospective studies, LDL particle concentration or apoB has been a stronger predictor of cardiovascular outcomes than LDL cholesterol. A recent analysis of the Framingham Offspring Study showed that LDL particle concentration was approximately twice as strongly related to CVD incidence as was LDL cholesterol ([@B6]). In individuals whose LDL cholesterol and LDL particle concentration were discordant, which was defined as having above-median LDL cholesterol and below-median LDL particle concentration (or vice versa), CVD event risk was associated more closely with LDL particle concentration than with LDL cholesterol ([@B6]).

Our analysis confirmed that, at equal doses, RSV was more effective than ATV for treating dyslipidemia in patients with the metabolic syndrome. For both statins, the percent reduction in LDL particleconcentration was smaller than that in LDL cholesterol, whereas, conversely, HDL particle concentration increases were greater than HDL cholesterol increases. These findings suggest the possibility that treating patients with the metabolic syndrome to targets based on LDL particle concentration rather than on LDL cholesterol may provide a more reliable approach to reducing residual CHD risk, but this remains to be established. The American Diabetes Association/American College of Cardiology Foundation consensus conference report recently suggested more aggressive lipoprotein goals for patients with the greatest cardiometabolic risk ([@B2]). This proposal is supported by our observation in patients with the metabolic syndrome that LDL particle concentration remains elevated in many patients who achieve LDL cholesterol goals. Further study will be needed to determine whether more stringent statin monotherapy or combination treatment, with the goal of further reducing LDLparticle concentration, will translate into better outcomes in patients with the metabolic syndrome.
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